Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio; Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
National Marrow Donor Program, Minneapolis, Minnesota.
Transplant Cell Ther. 2021 Feb;27(2):133-141. doi: 10.1016/j.jtct.2020.10.014. Epub 2020 Dec 11.
The impact of the coronavirus disease 2019 (COVID-19) pandemic on hematopoietic cell transplant (HCT) donor registries and transplant center (TC) practices is underreported. This article reports on the National Marrow Donor Program (NMDP) Be The Match Registry and its coordinating the provision of unrelated donor (URD) products to domestic and international TCs during the initial 3 months of the COVID-19 pandemic (March through May 2020). Specifically, NMDP data are presented for disease indications for transplant, URD search volumes and availability, graft requests and processing, courier utilization and performance, and conversion rates from formal donor search and workup to graft collection and shipment. Data following the onset of COVID-19 are compared to the immediate 3 months prior to the COVID-19 pandemic (December 2019 through February 2020) and the same quarter 1 year prior to COVID-19 (March through May 2019). During the initial onset of COVID-19 and compared to 1 year prior, TCs requested and the NMDP performed less donor searches. More multiple URD and direct to workup requests were processed by the NMDP, which likely reflected reductions in donor availability. Yet TCs continued to perform allogeneic transplants for acute disease indications like acute leukemia and myelodysplasia, using more cryopreserved grafts than before COVID-19. In comparison to prepandemic patient cycle conversion rates and durations, the NMDP was able to convert patient cycles at nearly the same or higher rates and in similar or shorter periods of time. Last, despite significant challenges caused by the pandemic, including interruptions in domestic courier services and travel restrictions, graft products were delivered to and received by TCs in similar periods of time than before COVID-19. Taken together, these data show that NMDP service line operations continued to function effectively during the early phases of the COVID-19 pandemic, ensuring requests for and delivery of URD products to domestic and international allogeneic HCT recipients.
2019 年冠状病毒病（COVID-19）大流行对造血细胞移植（HCT）供者登记处和移植中心（TC）实践的影响报道不足。本文报告了国家骨髓供者计划（NMDP）Be The Match 登记处及其在 COVID-19 大流行的最初 3 个月（2020 年 3 月至 5 月）期间协调向国内外 TC 提供非亲缘供者（URD）产品的情况。具体而言，NMDP 提供了移植疾病指征、URD 搜索量和可用性、移植物请求和处理、快递利用和绩效以及从正式供者搜索和检查到移植物采集和运输的转化率的数据。COVID-19 发病后的数据与 COVID-19 大流行前的最近 3 个月（2019 年 12 月至 2020 年 2 月）和 COVID-19 前一年的同一季度（2019 年 3 月至 5 月）进行了比较。在 COVID-19 发病初期，与前一年相比，TC 提出的要求和 NMDP 进行的供者搜索较少。NMDP 处理了更多的多份 URD 和直接检查请求，这可能反映了供者可用性的减少。然而，TC 继续为急性疾病指征（如急性白血病和骨髓增生异常综合征）进行同种异体移植，使用的冷冻保存移植物比 COVID-19 之前更多。与大流行前的患者周期转化率和持续时间相比，NMDP 几乎以相同或更高的速度并在相似或更短的时间内完成了患者周期的转换。最后，尽管受到大流行带来的重大挑战，包括国内快递服务中断和旅行限制，但在与 COVID-19 之前相似的时间段内，移植物产品被送到 TC 并被 TC 接收。总的来说，这些数据表明，NMDP 服务线运营在 COVID-19 大流行的早期阶段继续有效运作，确保了向国内外异基因 HCT 受者提供 URD 产品的请求和交付。
